July 19th 2022

Published in eBioMedicine: Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

Published in eBioMedicine: Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

The CARE partner Centre Institut National De La Santé Et De La Recherche Médicale – Vaccine Reserch Institute (INSERM-VRI) published a paper reporting on the design and testing of a protein subunit vaccine CD40.CoV2. The immunogenicity and antiviral efficacy of the vaccine was demonstrated in preclinical testing, and shown to be unaffected by Variants of Concern (VOC) mutations: indicating potential for enriching the available vaccine portfolio by extending the breadth of immune responses against current and emerging VOCs.

To learn more, click here: Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine